On this page · 4 sections→
Where the EU money came from
Funding by EU programme. Amounts are Atxa Therapeutics Ltd's own share of each project, not the project's full budget.
- Horizon Europe€2.5M · 1 project
- Horizon 2020€2.5M · 1 project
Projects
2 EU-funded projects, newest first. Atxa Therapeutics Ltd led 2 of them as coordinator. Each links to the official record.
- PAH-AdvanceCoordinator
PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).
Horizon Europe · 2023–2023 · Project on CORDIS ↗
€2.5Mtheir share - PAH-HOPECoordinator
New hope for the PAH patient: A Novel Therapeutic for Pulmonary Arterial Hypertension (PAH)
Horizon 2020 · 2018–2021 · Project on CORDIS ↗
€2.5Mtheir share
Fields it works in
Research fields recorded on its Horizon projects.
- cardiology
- cardiovascular diseases
- drug discovery
- drug safety
- pharmaceutical drugs
- pharmacokinetics
- pneumology
Is this your organisation?
Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.
Claim this profile →Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.